As an HDAC inhibitor, VPA may influence chromatin structure and gene expression by regulating protein and histone deacetylation, thereby ameliorating ALS pathology (Bankole et al., 2022). The gene discussed is HDAC9; the disease is amyotrophic lateral sclerosis.